Skye Bioscience, Inc.SKYE
What Skye Bioscience, Inc. does.
Skye Bioscience, Inc. is a clinical-stage biotechnology company pioneering next-generation molecules that modulate G-protein-coupled receptors ("GPCRs") to treat obesity, overweight, and metabolic disorders. Our lead candidate, nimacimab, is a peripherally restricted negative allosteric modulating antibody targeting cannabinoid receptor 1 ("CB1")—a key GPCR involved in metabolic regulation.
Except where the context indicates otherwise, references to "we," "us," "our," "Skye" or the" Company" refer to the company and its subsidiaries.
We believe there is a growing demand for therapies that offer improved safety, efficacy, tolerability, quality of life and long-term health outcomes while addressing the limitations of currently approved treatments. Our objective is to drive innovation in the treatment landscape for obesity, overweight and metabolic disorders by developing potential first-in-class therapies that meet significant unmet medical needs globally.
Revenue and profit, by fiscal year.
| Fiscal year | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Net income | -$6.6M | -$8.5M | -$19.5M | -$37.6M | -$26.6M | -$55.9M |
| Free cash flow | -$6.1M | -$6.6M | -$12.8M | -$14.0M | -$26.8M | -$43.1M |
More on SKYE.
- Skye Bioscience, Inc. summary
- Skye Bioscience, Inc. financial statements
- Skye Bioscience, Inc. key metrics
- Skye Bioscience, Inc. health scores and style box
- Skye Bioscience, Inc. earnings
- Skye Bioscience, Inc. dividends
- Skye Bioscience, Inc. valuation
- Skye Bioscience, Inc. ownership and insiders
- Skye Bioscience, Inc. peers
Figures from Skye Bioscience, Inc.'s filings with the U.S. SEC, standardised automatically; prices are end-of-day closes. Not financial advice.